CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 176 enrolled
Drug / intervention
Dexcom G6 CGM System +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03566693
NCT03566693N/ACompleted
CompareCT.gov

Continuous Glucose Monitoring (CGM) in Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)

DexCom, Inc.·interventional·Posted Jun 25, 2018·Updated Apr 21, 2021

In Brief

A clinical study evaluating Dexcom G6 CGM System and Blood glucose meter for Diabetes Mellitus, Type 2. Completed, enrolled 176 participants across 15 sites.

Detailed Summary

A study to compare the glycemic and quality of life benefits of diabetes management using Dexcom G6 continuous glucose monitoring (CGM) or self-monitored blood glucose (SMBG) made by study participants and their primary care physicians. Decisions will be based on insights from real-time use and retrospective insights, determined during remote visits. Participants will have type 2 diabetes and be using basal insulin (with or without oral medications and/or Glucagon-Like-Peptide-1 (GLP-1) analogue) and have an elevated Hemoglobin A1C (HbA1c).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
CollaboratorsJaeb Center for Health Research

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJun 25, 2018
Enrollment StartJul 30, 2018
Primary CompletionJan 4, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.0 years ago

Interventions

Dexcom G6 CGM Systemdevice

continuous glucose monitor

Blood glucose meterdevice

Blue-tooth enabled blood glucose meter